



Proteomics International
LABORATORIES LTD

ASX/Media Release

6 September 2017

ASX code: PIQ

PromarkerD clinical study published in peer-reviewed international journal *Diabetes Care*

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a leader in predictive diagnostics and analytical services, announces the publication of a clinical research paper about its flagship diagnostic test, PromarkerD, which can predict the onset of diabetic kidney disease better than any current measure.

- **PromarkerD test published in leading scientific journal *Diabetes Care*, shows “prediction of rapid decline in renal function independently of recognised clinical risk factors”**
- **The community based clinical study predicted patients at risk of developing diabetic kidney disease over a four year period**
- **If unchecked, the International Diabetes Federation estimates the adult population with diabetes will be 642 million by 2040, and currently one in three diabetics have chronic kidney disease**
- **PromarkerD has the potential to save healthcare systems around the world billions of dollars in costs with predictive and preventative diabetic kidney disease management**
- **The Company moves forward with its commercialisation plans in key markets around the world**

The PromarkerD research was published in *Diabetes Care*, the journal of the American Diabetes Association and one of the top two diabetes publications globally. The publication titled “Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II” provides an important verification of the test, which can predict the onset of diabetic kidney disease better than any current measure.

The clinical study, undertaken as a collaboration between Proteomics International and The University of Western Australia, describes the clinical development study used to create the revolutionary predictive test for diabetic kidney disease, including the identification of protein ‘fingerprints’ for the condition. These fingerprints, or biomarkers, can be detected with a simple blood test.

According to the International Diabetes Federation, 415 million adults had diabetes in 2015, estimated to rise to 642 million by 2040. Currently, one in three adult diabetics have chronic kidney disease, which, if unchecked, means the number with chronic kidney disease will increase by 76 million over the period. The current cost of dialysis is estimated at \$100,000 per person per year.

Proteomics International managing director Dr Richard Lipscombe said *Diabetes Care* leads the way in original diabetes research. “This prestigious journal is widely read by health professionals and diabetes experts around the world,” he said.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

“Publishing our research after appraisal by independent experts in the field is a key part of our strategy for engaging with key opinion leaders as we work to commercialise PromarkerD. With the methods and clinical findings behind the test freely available, doctors, researchers and diabetes educators can have confidence in adopting PromarkerD for diabetes patients.”

The results of the study were previously presented alongside the latest clinical data at the 77th Annual Scientific Sessions of the American Diabetes Association in San Diego (ASX release 13 June 2017), and also at the Australian Diabetes Society conference in Perth last week.

The research was published online on the 29th August for members of the American Diabetes Association ahead of print in the journal's November issue. It is available at:
<http://care.diabetesjournals.org/content/early/2017/08/24/dc17-0911>

ENDS

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Paul Hart [Investor Relations]
Director
Canary Capital
T: +61 421 051 474
E: phart@canarycapital.com.au

Susan Fitzpatrick-Napier [Media Contact]
Digital Mantra Group
T: +61 2 8218 2144
E: team@dmgpr.com

The Fremantle Diabetes Study (FDS)

The Fremantle diabetes Study is a longitudinal observational study of a community-based, urban population in Fremantle, Western Australia. The study, which commenced in 1993 with a more recent phase II in 2008, contains over 3,000 recruits, and is headed by Professor Tim Davis of Fremantle Hospital and the Medical School at The University of Western Australia.

The strengths of the FDS are the inclusive and representative nature of the cohorts, the range and detail of data collection and linkage to well-established morbidity and mortality databases. The design and implementation of the FDS means that specific questions regarding the natural history of diabetes, its impact on the individual and its costs can be addressed with relative rigour.

The University of Western Australia

Ranked in the world's top 100 universities, The University of Western Australia (UWA) is Western Australia's first university and has an international reputation for excellence in education, research and community engagement. The University is located alongside the Swan River, five kilometres from the heart of Perth city. UWA's cutting-edge research attracts high levels of competitive research funding and researchers who are global leaders in their field.

Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company focused on proteomics – the industrial scale study of the structure and function of proteins. PILL is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on the QEII Medical Campus in Perth, Western Australia. The Company's business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com